Nasdaq

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Business Wire

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was ...
Nasdaq

FDA Grants Breakthrough Device Designation to Natera's Signatera Test

SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its ...
MedTech Dive

Natera wins FDA approval for companion diagnostic

The test will enable physicians to assess if post-surgery cancer patients need to receive treatment to minimize the risk of ...
Business Wire

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Business Insider

Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...
Yahoo Finance

Natera’s Signatera test to be used in Phase III bladder cancer trial

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
Hosted on MSN

Natera's Signatera data suggests select breast cancer patients could skip surgery

Natera Inc. NTRA shares are up on Tuesday as the company announced promising results from a prospective study regarding its Signatera molecular residual disease (MRD) test. • Natera stock is showing ...

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology ...
WFLA News Channel 8

Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

AUSTIN, Texas, Jan. 22, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical utility ...
Insider Monkey

Signatera Oncology Test Drives Natera’s (NTRA) Growth

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.
Seeking Alpha

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...